{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:28:24Z","timestamp":1792787304425,"version":"4.5.0"},"reference-count":26,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"unspecified","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"GSK","award":["212866"],"award-info":[{"award-number":["212866"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2024,11,8]]},"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate modified versions of the Belimumab International Study in Lupus Nephritis (BLISS-LN) belimumab study primary efficacy renal response (mPERR) and complete renal response (mCRR) criteria (excluding mandatory corticosteroid tapering) as predictors of real-world, long-term renal outcomes among patients with lupus nephritis (LN).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective, observational study (GSK Study 212866) used deidentified data between 1970 and 2015 from the University of Toronto Lupus Cohort from adults diagnosed with systemic lupus erythematosus and biopsy-proven Class III\u00b1V, IV\u00b1V or V LN. At 24 months postbiopsy, patients were retrospectively indexed as responders\/non-responders based on mPERR (estimated glomerular filtration rate (eGFR) \u226420% below biopsy value\/\u226560\u2009mL\/min\/1.73\u2009m\n                      <jats:sup>2<\/jats:sup>\n                      and urine protein:creatinine ratio (uPCR) \u22640.7\u2009g\/day) or mCRR (eGFR \u226410% below biopsy value\/\u226590\u2009mL\/min\/1.73\u2009m\n                      <jats:sup>2<\/jats:sup>\n                      and uPCR \u22640.5\u2009g\/day) criteria. The association between index mPERR (primary outcome) or mCRR (secondary outcome) status and long-term (up to 25 years, until censoring or death) renal survival (no progression to end-stage kidney disease (eGFR &lt;30\u2009mL\/min\/1.73\u2009m\n                      <jats:sup>2<\/jats:sup>\n                      , dialysis or transplant) or death) was assessed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 179 patients were included in the analysis (mPERR responders, n=128; non-mPERR responders, n=51). Most patients were female (87.2%); the mean (SD) age was 34.1 (11.3) years.<\/jats:p>\n                    <jats:p>Long-term renal survival was attained for 78.9% of mPERR responders and 60.8% of non-mPERR responders; achieving mPERR was associated with an increased likelihood of long-term renal survival versus not achieving mPERR (log-rank p=0.0119). Overall, 102 patients were mCRR responders, and 77 were non-mCRR responders. Long-term renal survival was attained for 80.4% of mCRR responders and 64.9% of non-mCRR responders; achieving mCRR was associated with an increased likelihood of long-term renal survival than not achieving mCRR (log-rank p=0.0259).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Achieving mPERR or mCRR was associated with improved long-term renal survival, highlighting that these statuses are suitable predictors of long-term renal outcomes in patients with LN.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/lupus-2024-001264","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T04:13:15Z","timestamp":1732767195000},"page":"e001264","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Renal response status to predict long-term renal survival in patients with lupus nephritis: results from the Toronto Lupus Cohort"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct01639339","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7506-9166","authenticated-orcid":false,"given":"Murray","family":"Urowitz","sequence":"first","affiliation":[{"name":"Division of Rheumatology, University of Toronto Lupus Program, Schroeder Arthritis Institute, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6225-2164","authenticated-orcid":false,"given":"Mary E","family":"Georgiou","sequence":"additional","affiliation":[{"name":"Value Evidence and Outcomes, GSK, Brentford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5177-2076","authenticated-orcid":false,"given":"Zahi","family":"Touma","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, University of Toronto Lupus Program, Schroeder Arthritis Institute, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiandong","family":"Su","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, University of Toronto Lupus Program, Schroeder Arthritis Institute, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Diaz-Martinez","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, University of Toronto Lupus Program, Schroeder Arthritis Institute, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinggong","family":"Fu","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, GSK, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6393-6031","authenticated-orcid":false,"given":"Roger A","family":"Levy","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, GSK, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Gairy","sequence":"additional","affiliation":[{"name":"Value Evidence and Outcomes, GSK, Brentford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"MacKinnon","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, University of Toronto Lupus Program, Schroeder Arthritis Institute, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Anderson","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, University of Toronto Lupus Program, Schroeder Arthritis Institute, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia C","family":"Juliao","sequence":"additional","affiliation":[{"name":"Value Evidence and Outcomes, GSK, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"key":"2025091512180246000_11.2.e001264.1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40930"},{"key":"2025091512180246000_11.2.e001264.2","doi-asserted-by":"publisher","DOI":"10.1097\/01.md.0000091181.93122.55"},{"key":"2025091512180246000_11.2.e001264.3","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev311"},{"key":"2025091512180246000_11.2.e001264.4","doi-asserted-by":"publisher","DOI":"10.1007\/BF01451283"},{"key":"2025091512180246000_11.2.e001264.5","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.10.017"},{"key":"2025091512180246000_11.2.e001264.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.01.055"},{"key":"2025091512180246000_11.2.e001264.7","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2020-000389","article-title":"Prediction of prognosis and renal outcome in lupus nephritis","volume":"7","author":"Parodis","year":"2020","journal-title":"Lupus Sci Med"},{"key":"2025091512180246000_11.2.e001264.8","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/art.39594","article-title":"Risk of End-Stage Renal Disease in Patients With Lupus Nephritis, 1971-2015: A Systematic Review and Bayesian Meta-Analysis","volume":"68","author":"Tektonidou","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025091512180246000_11.2.e001264.9","first-page":"257","article-title":"Disease-specific quality of life in patients with lupus nephritis","volume":"27","author":"Jolly","year":"2018","journal-title":"Lupus (Los Angel)"},{"key":"2025091512180246000_11.2.e001264.10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s40744-021-00368-y","article-title":"The Economic Burden of Lupus Nephritis: A Systematic Literature Review","volume":"9","author":"Thompson","year":"2022","journal-title":"Rheumatol Ther"},{"key":"2025091512180246000_11.2.e001264.11","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-015-0621-6","article-title":"Comparison and evaluation of lupus nephritis response criteria in lupus activity indices and clinical trials","volume":"17","author":"Corapi","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2025091512180246000_11.2.e001264.12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220920"},{"key":"2025091512180246000_11.2.e001264.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.05.021"},{"key":"2025091512180246000_11.2.e001264.14","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00578-x"},{"key":"2025091512180246000_11.2.e001264.15","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.4492","article-title":"Effect of Tacrolimus vs Intravenous Cyclophosphamide on Complete or Partial Response in Patients With Lupus Nephritis","volume":"5","author":"Zheng","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025091512180246000_11.2.e001264.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001180"},{"key":"2025091512180246000_11.2.e001264.17","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000598","article-title":"Renal response at 2 years post biopsy to predict long-term renal survival in lupus nephritis: a retrospective analysis of the Hopkins Lupus Cohort","volume":"9","author":"Cooper Blenkinsopp","year":"2022","journal-title":"Lupus Sci Med"},{"key":"2025091512180246000_11.2.e001264.18","unstructured":"GSK . FDA approves GSK\u2019s BENLYSTA as the first medicine for adult patients with active lupus nephritis in the US. 2024. Available: https:\/\/us.gsk.com\/en-us\/media\/press-releases\/fda-approves-gsk-s-benlysta-as-the-first-medicine-for-adult-patients-with-active-lupus-nephritis-in-the-us\/"},{"key":"2025091512180246000_11.2.e001264.19","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"2025091512180246000_11.2.e001264.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214819"},{"key":"2025091512180246000_11.2.e001264.21","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-217105","article-title":"Response to: \u201cDo 2019 European League against rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus also indicate the disease activity?\u201d by Teng et al","volume":"81","author":"Aringer","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025091512180246000_11.2.e001264.22","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224762"},{"key":"2025091512180246000_11.2.e001264.23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215089"},{"key":"2025091512180246000_11.2.e001264.24","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","article-title":"KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"2025091512180246000_11.2.e001264.25","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.161554"},{"key":"2025091512180246000_11.2.e001264.26","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/1756-185X.14982","article-title":"Poster Abstracts","volume":"27","year":"2024","journal-title":"Int J of Rheum Dis"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2024-001264","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T19:18:08Z","timestamp":1757963888000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2024-001264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,11,27]]},"published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1136\/lupus-2024-001264"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2024-001264","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]}}}